Recent 8-K filings for BRNS

• April 30, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track

  Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.

• March 13, 2026, 7:59 PM ET M&A materiality 0.85 neutral item 2.02item 7.01item 9.01

  Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026

  Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.

• January 6, 2026, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR

  On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).

• December 10, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease

  VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.

• November 7, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog

  Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.

• September 30, 2025, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 7.01item 9.01

  Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company

  Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.

• August 8, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M

  Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027

  Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.

• May 7, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 5.02item 7.01item 8.01item 9.01 ◈ executive_change ×3

  Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data

  Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.

• March 20, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025

  Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.

• January 10, 2025, 6:59 PM ET other material materiality 0.85 negative item 2.02item 2.05item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000

  Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.

• November 15, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b

  IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.

• November 6, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026

  Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.

• August 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired

  Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.

• June 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01

  Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026

  Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.

• June 6, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo

  HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.

• May 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 7.01item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed

  Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.

• May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial

  Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

5 positive 5 negative 16 neutral

source · BRNS on sec.gov